SCHEMBL15469382

SCHEMBL15469382

Cc1ccc(C2(O)CCCc3cccnc32)cc1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.34
CYP11B1 P15538 3/20 0.34
CYP11B2 P19099 3/20 0.34
OPRL1 P41146 3/20 0.34
SIGMAR1 Q99720 2/20 0.34
CYP17A1 P05093 2/20 0.34
OPRM1 P35372 2/20 0.34
OPRK1 P41145 2/20 0.34
PDK2 Q15119 1/20 0.33
FNTA P49354 1/20 0.33
FNTB P49356 1/20 0.33
HSD11B1 P28845 3/20 0.32
HSD11B2 P80365 3/20 0.32
ALDH1A1 P00352 2/20 0.32
OPRD1 P41143 1/20 0.32
GAA P10253 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
AKR1B1 P15121 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4196936 0.87 CYP3A4 (0.47) CYP3A4CYP11B1CYP11B2CYP17A1FNTA
SCHEMBL15467881 0.83 TRPV1 (0.37) CYP3A4CYP11B1CYP11B2OPRL1CYP17A1
SCHEMBL15469383 0.79 KDM1A (0.36) SIGMAR1HSD11B1HSD11B2ALDH1A1GAA
SCHEMBL2148122 0.78 OPRL1 (0.42) OPRL1SIGMAR1PDK2FNTAFNTB
SCHEMBL15467925 0.77 MAP3K14 (0.41) OPRL1OPRM1OPRK1PDK2ALDH1A1
SCHEMBL23364947 0.75 CYP1A2 (0.39) OPRL1SIGMAR1FNTAFNTBKMT2A
SCHEMBL15894663 0.75 CYP1A2 (0.39) OPRL1SIGMAR1FNTAFNTBKMT2A
SCHEMBL26833404 0.74 OPRL1 (0.33) OPRL1SIGMAR1PDK2FNTAFNTB
SCHEMBL15469384 0.72 SIGMAR1 (0.30) SIGMAR1
SCHEMBL4070387 0.71 KDM1A (0.42) OPRL1SIGMAR1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8952009-B2 Chroman derivatives as TRPM8 inhibitors AMGEN INC. (US) 2015-02-10 US disclosed
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC (US) 2015-01-29 US disclosed
US-20140045855-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC. (US) 2014-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS TRPM8, TRPM5, TRPM7 CYP3A4 1842/4885CYP11B1 2943/4885CYP11B2 2859/4885
US-20140045855-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS TRPM8, TRPM5, TRPM7 CYP3A4 1842/4885CYP11B1 2943/4885CYP11B2 2859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.